Search Results | MSF Science Portal

Journal Article

|

Research

Sinha A, Klebe R, Rekart ML, Alvarez JL, Skrahina A, et al.

2025-02-18 • Clinical Infectious Diseases

BACKGROUND

Only 63% of patients initiating multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment in 2020 were treated successfully. 24-Wee...

Journal Article

|

Research

Sweeney S, Laurence YV, Berry C, Singh MP, Dodd M, et al.

2025-02-01 • Lancet Global Health

BACKGROUND

New 6-month rifampicin-resistant tuberculosis treatment regimens containing bedaquiline, pretomanid, and linezolid (BPaL) with or without moxifloxaci...

Journal Article

|

Research

Moe S, Azamat I, Allamuratova S, Oluya M, Khristusev A, et al.

2024-09-01 • IJTLD OPEN

BACKGROUND

Dru...

Journal Article

|

Research

Rekart M, Thit P, Oluya M, Moe S, Hasan T, et al.

2024-07-01 • IJTLD OPEN

Background

Isoniazid (INH, H) resistance is the most common drug-resistant TB pattern, with treatment success rates lower than those in drug-susceptible TB. The...

Journal Article

|

Research

Motta I, Cusinato M, Ludman AJ, Lachenal N, Dodd M, et al.

2024-06-06 • Antimicrobial Agents and Chemotherapy

Regimens for the treatment of rifampicin-resistant tuberculosis currently rely on the use of QT-prolonging agents. Using data from the randomized controlled trial, TB-PRACTECAL, we inves...

Journal Article

|

Review

Hasan T, Medcalf E, Nyang'wa BT, Egizi E, Berry C, et al.

2024-03-20 • Clinical Infectious Diseases

BACKGROUND
Effectiveness, safety, tolerability, and adherence are critical considerations in shifting to shorter tuberculosis (TB) regimens. Novel 6-month oral regimens that include ...

Journal Article

|

Research

Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, et al.

2024-02-01 • Lancet Respiratory Medicine

BACKGROUND
Around 500,000 people worldwide develop rifampicin-resistant tuberculosis each year. The proportion of successful treatment outcomes remains low and new treatments are nee...

Conference Material

|

Poster

Motta I, Cusinato M, Ludman A, Abdrasuliev T, Butabekov I, et al.

2023-06-07 • MSF Scientific Day International 2023

Conference Material

|

Slide Presentation

Stringer B, Lowton K, Cusinato M, Fielding K, Liverko I, et al.

2023-06-07 • MSF Scientific Day International 2023

Conference Material

|

Video

Stringer B

2023-06-07 • MSF Scientific Day International 2023

Conference Material

|

Abstract

Stringer B, Lowton K, Cusinato M, Fielding K, Liverko I, et al.

2023-06-07 • MSF Scientific Day International 2023

INTRODUCTION
The TB-PRACTECAL study trialed a shorter, more tolerable regimen of oral drugs than standard of care (SoC) – which can last for up to 20 months and involve both injectab...

Journal Article

|

Research

Moe S, Rekart ML, Hernandez D, Sholpan A, Ismailov A, et al.

2023-05-01 • International Journal of Tuberculosis and Lung Disease

BACKGROUND:
Bedaquiline (BDQ) is widely used in the treatment of rifampicin-resistant TB (RR-TB). However, resistance to BDQ is now emerging. There are no standardised regimens for ...

Journal Article

|

Research

Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, et al.

2022-12-22 • New England Journal of Medicine

BACKGROUND
In patients with rifampin-resistant tuberculosis, all-oral treatment regimens that are more effective, shorter, and have a more acceptable side-effect profile than current...

Journal Article

|

Research

Kohler S, Sitali N, Achar J, Paul N

2022-11-23 • Journal of Public Health

BACKGROUND
Tuberculosis (TB) drugs and their import are costly. We assessed how shorter TB drug regimens, which were non-inferior or superior in recent TB trials, can affect the cost...

Journal Article

|

Research

Kohler S, Sitali N, Achar J, Paul N

2022-08-03 • PLOS Global Public Health

Tuberculosis (TB) programs depend on a continuous supply of large amounts of high-quality TB drugs. When TB programs procure TB drugs from international suppliers, such as the Global ...

Journal Article

|

Research

Bonnet MMB, Sizaire V, Kebede YYK, Janin A, Doshetov D, et al.

2005-10-01 • International Journal of Tuberculosis and Lung Disease

SETTING: After the collapse of the Soviet Union, countries in the region faced a dramatic increase in tuberculosis cases and the emergence of drug resistance. OBJECTIVE: To discuss the r...

Journal Article

|

Letter

Bastard M, Bonnet MMB, du Cros PAK, Khamraev AK, Hayrapetyan A, et al.

2015-02-01 • American Journal of Respiratory and Critical Care Medicine

Journal Article

|

Research

Gadoev J, Asadov D, Tillashaykhov M, Tayler-Smith K, Isaakidis P, et al.

2015-06-15 • PLOS One

BACKGROUND
TB is one of the main health priorities in Uzbekistan and relatively high rates of unfavorable treatment outcomes have recently been reported. This requires closer analysi...

Protocol

|

Research Protocol

Sweeney S, Gomez G, Kitson N, Sinha A, Yatskevich N, et al.

2020-10-10 • BMJ Open

INTRODUCTION
Current treatment regimens for multidrug-resistant tuberculosis (MDR-TB) are long, poorly tolerated and have poor outcomes. Furthermore, the costs of treating MDR-TB are...

Journal Article

|

Letter

Cox HS, Sibilia C, Feuerriegel S, Kalon S, Polonsky JA, et al.

2008-11-27 • New England Journal of Medicine

Science Portal

The effectiveness and safety of bedaquiline, pretomanid, and linezolid (BPaL)-based regimens for rifampicin-resistant tuberculosis in non-trial settings - A prospective cohort study in Belarus and Uzbekistan

24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation

Second-line drug-resistant TB and associated risk factors in Karakalpakstan, Uzbekistan

A 10-year review of isoniazid-resistant TB management in Uzbekistan 2009-2020

How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial

The safety and tolerability of linezolid in novel short-course regimens containing bedaquiline, pretomanid, and linezolid to treat rifampicin-resistant tuberculosis: An individual patient data meta-analysis

Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial

ECG findings in BPaL-based TB treatment regimens: the geographical effect on QT prolongation

Patient-reported experiences and quality of life outcomes in the TB-PRACTECAL clinical trial (PRACTECAL-PRO): a mixed-methods, multi-site study

Patient-reported experiences and quality of life outcomes in the TB-PRACTECAL clinical trial (PRACTECAL-PRO): a mixed-methods, multi-site study

Patient-reported experiences and quality of life outcomes in the TB-PRACTECAL clinical trial: PRACTECAL-PRO

Primary bedaquiline resistance in Karakalpakstan, Uzbekistan

A 24-week, all-oral regimen for rifampin-resistant tuberculosis

Costs and import costs of past, present, and future TB drug regimens: a case study for Karakalpakstan, Uzbekistan

The contribution of drug import to the cost of tuberculosis treatment: A cost analysis of longer, shorter, and short drug regimens for Karakalpakstan, Uzbekistan

Does One Size Fit All? Drug Resistance and Standard Treatments: Results of Six Tuberculosis Programmes in Former Soviet Countries

Revised definitions of multidrug-resistant tuberculosis treatment outcomes: closer to the reality?

Factors associated with unfavorable treatment outcomes in new and previously treated TB patients in Uzbekistan: a five year countrywide study

Cost-effectiveness of new MDR-TB regimens: study protocol for the TB-PRACTECAL economic evaluation substudy

Emergence of extensive drug resistance during treatment for multidrug-resistant tuberculosis